• 1
    Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol 1998; 25: 25564.
  • 2
    Rosenthal A, Jacobs I. Ovarian cancer screening [published erratum appears in Semin Oncol 1998 Dec;25(6):707]. Semin Oncol 1998; 25: 31525.
  • 3
    Kasprzak L, Foulkes WD, Shelling AN. Fortnightly review: hereditary ovarian carcinoma. BMJ 1999; 318: 7869.
  • 4
    Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1184203.
  • 5
    Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998; 351: 1047.
  • 6
    Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 9036.
  • 7
    Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD, Shapiro S. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 9337.
  • 8
    Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002; 13: 53542.
  • 9
    Rodriguez C, Henley SJ, Calle EE, Thun MJ. Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA. Lancet 1998; 352: 13545.
  • 10
    Friis S, Nielsen GL, Mellemkjaer L, McLaughlin JK, Thulstrup AM, Blot WJ, Lipworth L, Vilstrup H, Olsen JH. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 2002; 97: 96101.
  • 11
    Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002; 22: 3039.
  • 12
    Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2000; 11: 11713.
  • 13
    Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer [see comments]. J Natl Cancer Inst 1999; 91: 145967.
  • 14
    Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE, Grizzle WE. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002; 8: 2029.
  • 15
    Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90: 177486.
  • 16
    Harlow BL, Cramer DW. Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies. Cancer Causes Control 1995; 6: 1304.
  • 17
    Harlow BL, Cramer DW, Baron JA, Titus-Ernstoff L, Greenberg ER. Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 697702.
  • 18
    Dalton SO, Johansen C, Mellemkjaer L, Sorenson HT, McLaughlin JK, Olsen J, Olsen JH. Antidepressant medications and risk for cancer. Epidemiology 1999; 11: 1716.
  • 19
    Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE. Psychotropic medication use and risk of hormone-related cancers: the New York University Women's Health Study. J Public Health Med 2000; 22: 15560.
  • 20
    Michnovicz JJ, Galbraith RA. Cimetidine inhibits catechol estrogen metabolism in women. Metabolism 1991; 40: 1704.
  • 21
    Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994; 5: 491500.
  • 22
    Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 48591.
  • 23
    Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288: 33441.
  • 24
    Preston DL, Lubin J, Pierce DA, McConney ME. EPICURE [software], Release 2.0 ed. Seattle, WA: HiroSoft International Corp., 1996.
  • 25
    Breslow NE, Day NE. Statistical methods in cancer research. vol. II. The design and analysis of cohort studies. Lyon: International Agency for Research on Cancer, 1987.
  • 26
    Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med 2001; 33: 6827.
  • 27
    Dublin S, Rossing MA, Heckbert SR, Goff BA, Weiss NS. Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control 2002; 13: 3545.
  • 28
    Tutton PJM, Barkla DH. Comparison of the tumor inhibiting effects of three histamine H2-receptor antagonists. Anticancer Res 1983; 3: 710.
  • 29
    Rossing MA, Scholes D, Cushing-Haugen KL, Voigt LF. Cimetidine use and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 31923.
  • 30
    West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142: 110312.